



## Ultragenyx to Participate at Investor Conferences in September

August 31, 2023

*Citi BioPharma Conference on September 6 in Boston*

*Morgan Stanley Healthcare Conference on September 12 in New York City*

NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a panel discussion at Citi's 18<sup>th</sup> Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21<sup>st</sup> Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST.

The live and archived webcast of the panel and fireside chat will be accessible from the company's website at <https://ir.ultragenyx.com/events-presentations>.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: [www.ultragenyx.com](http://www.ultragenyx.com).

Contacts – Ultragenyx Pharmaceutical, Inc.

Investors

Joshua Higa

[ir@ultragenyx.com](mailto:ir@ultragenyx.com)

Media

Jeff Blake

[media@ultragenyx.com](mailto:media@ultragenyx.com)